Skip to main content
    J

    Jasper Therapeutics Inc (JSPRW)

    Official site

    BIOTECHNOLOGY • NASDAQ

    $0.00
    +0.00 (+0.00%)

    Last updated: Sep 25, 2026 at 5:00 PM ET

    Jasper Therapeutics Inc (JSPRW) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Jasper Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$75.80M, operating cash flow was -$77.16M and free cash flow was -$77.17M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$2.76M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $80.52M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$1.06M$1.37M$1.11M$1.31M$566.00K$21.00KN/A
    Gross profit-$1.06M-$1.37M-$1.11M-$1.31M-$566.00K-$21.00KN/A
    Research and development$60.52M$55.82M$51.78M$34.63M$25.42M$15.88M$3.62M
    Operating income-$80.52M-$76.24M-$68.86M-$51.20M-$36.83M-$20.68M-$4.71M
    Net income-$75.80M-$71.27M-$64.47M-$37.69M-$30.64M-$31.67M-$4.99M
    EBITDA-$74.75M-$69.90M-$63.36M-$36.71M-$30.26MN/A-$277.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$0$0$0$0$1.17M$0$0$0$2.05M$0
    Gross profitN/A-$21.00K-$290.00KN/A-$258.00K-$279.00K$587.00K-$541.00K-$299.00K-$288.00K-$82.00K-$276.00K
    Operating income-$9.21M-$10.95M-$15.84M-$19.17M-$27.08M-$21.80M-$25.29M-$19.89M-$15.99M-$15.07M-$17.73M-$19.36M
    Net income-$2.76M-$1.17M-$9.10M-$18.74M-$26.72M-$21.24M-$24.32M-$18.64M-$14.58M-$13.73M-$16.58M-$17.54M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.24M by $27.46M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$35.78M$79.90M$94.89M$48.36M$93.65M$23.36M$27.21M
    Current assets$34.65M$75.81M$88.94M$41.73M$87.83M$20.68M$27.16M
    Cash and equivalents$28.69M$71.64M$86.89M$38.25M$84.70M$19.84M$27.16M
    Total liabilities$31.63M$18.23M$16.45M$12.37M$24.14M$58.49M$6.11M
    Short-term debt$1.24M$1.09M$972.00K$865.00K$505.00KN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$13.13MN/A
    Shareholder equity$4.15M$61.67M$78.44M$35.99M$69.52M-$35.13M$21.10M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$11.80M$21.18M$35.78M$57.47M$46.47M$57.60M$79.90M$99.41M$113.93M$125.96M$94.89M$110.41M
    Total liabilities$10.39M$17.78M$31.63M$45.90M$22.96M$15.35M$18.23M$15.73M$13.62M$12.73M$16.45M$16.27M
    Cash and equivalents$7.31M$14.14M$28.69M$50.90M$39.51M$48.80M$71.64M$92.50M$106.82M$118.47M$86.89M$103.87M
    Shareholder equity$1.41M$3.40M$4.15M$11.57M$23.50M$42.24M$61.67M$83.68M$100.31M$113.23M$78.44M$94.13M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$77.16M-$62.60M-$52.07M-$45.86M-$33.68M-$18.27M-$1.97M
    Capital expenditures$7.00K$552.00K$267.00K$576.00K$2.43M$0$0
    Free cash flow-$77.17M-$63.15M-$52.33M-$46.43M-$36.11M-$18.27M-$1.97M
    Investing cash flow$5.00K-$532.00K-$267.00K-$576.00K-$2.43M$198.34KN/A
    Financing cash flow$34.21M$47.88M$100.97M$55.00K$100.97M$11.29M$29.13M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$6.92M-$14.55M-$21.87M-$17.00M-$15.45M-$22.84M-$21.13M-$14.05M-$11.68M-$15.74M-$16.48M-$11.98M
    Capital expenditures$0$0$0$0$7.00K$0$96.00K$274.00K$157.00K$25.00K$230.00K$0
    Free cash flow-$6.92M-$14.55M-$21.87M-$17.00M-$15.46M-$22.84M-$21.23M-$14.33M-$11.84M-$15.76M-$16.71M-$11.98M
    Last 12 quarters

    Frequently Asked Questions About JSPRW

    What is Jasper Therapeutics' annual revenue?

    Jasper Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Jasper Therapeutics profitable?

    No. Jasper Therapeutics reported net income of -$75.80M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does JSPRW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$77.16M minus capital expenditures of $7.00K produced free cash flow of -$77.17M.

    How much debt does Jasper Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.24M and cash and equivalents of $28.69M.